SHR 117887Alternative Names: SHR-117887
Latest Information Update: 24 Feb 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action CD26 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 24 Feb 2016 No recent reports on development identified - Phase-II for Type-2 diabetes mellitus (Combination therapy) in China (PO)
- 30 Jun 2012 Phase-II clinical trials in Type-2 diabetes mellitus in China (PO)